

Cone Health's Evaluation of Babyscripts' Impact on Outcomes at Delivery

OBJECTIVE { Evaluate Babyscripts' impact on reductions in adverse delivery events, length of stay and cost savings.

KEY TAKEAWAYS

For patients enrolled in Babyscripts before delivery

- **59.4% reduced risk** of developing anemia during the delivery visit
- Anemic patients were **27.8% less likely to exceed MS-DRG**
- **13 day reduction** in the time to detect preeclampsia, utilizing remote blood pressure monitoring
- **17.7% reduced risk** of NICU stays during delivery visit (from extended analysis with a similar cohort, 2018-2021)


METHODS

2017 - 2020

- Multiyear data analysis of delivery outcomes controlled for age, race, payer and comorbidity burden
 - 3,252 = case
 - 3,252 = control
- Poisson models with Huber-White robust standard errors reporting incident risk ratios used for clinical outcomes. Models adjusted for:
 - Actual LOS
 - Visits prior to the delivery encounter
 - Average Braden score (activity, nutrition, mobility) during the delivery visit
 - DRG
 - Marital status
 - Provider ID
 - Postpartum hemorrhage risk score
 - C-section vs. vaginal delivery

Use of Babyscripts associated with **reduced risk for adverse delivery outcomes**, earlier identification of preeclampsia, and cost savings related to averting anemia and reducing NICU stays.

CASE POPULATION BY % RACE



CASE POPULATION BY % PAYER

